Anti-ACHA7/ CHRNA7/ CHRNA7-2 monoclonal antibody

Anti-ACHA7/ CHRNA7/ CHRNA7-2 antibody for FACS & in-vivo assay

Target products collectionGo to CHRNA7/CHRNA7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T34429-Ab-1/ GM-Tg-hg-T34429-Ab-2Anti-Human CHRNA7 monoclonal antibodyHuman
GM-Tg-rg-T34429-Ab-1/ GM-Tg-rg-T34429-Ab-2Anti-Rat CHRNA7 monoclonal antibodyRat
GM-Tg-mg-T34429-Ab-1/ GM-Tg-mg-T34429-Ab-2Anti-Mouse CHRNA7 monoclonal antibodyMouse
GM-Tg-cynog-T34429-Ab-1/ GM-Tg-cynog-T34429-Ab-2Anti-Cynomolgus/ Rhesus macaque CHRNA7 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T34429-Ab-1/ GM-Tg-felg-T34429-Ab-2Anti-Feline CHRNA7 monoclonal antibodyFeline
GM-Tg-cang-T34429-Ab-1/ GM-Tg-cang-T34429-Ab-2Anti-Canine CHRNA7 monoclonal antibodyCanine
GM-Tg-bovg-T34429-Ab-1/ GM-Tg-bovg-T34429-Ab-2Anti-Bovine CHRNA7 monoclonal antibodyBovine
GM-Tg-equg-T34429-Ab-1/ GM-Tg-equg-T34429-Ab-2Anti-Equine CHRNA7 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T34429-Ab-1/ GM-Tg-hg-T34429-Ab-2; GM-Tg-rg-T34429-Ab-1/ GM-Tg-rg-T34429-Ab-2;
GM-Tg-mg-T34429-Ab-1/ GM-Tg-mg-T34429-Ab-2; GM-Tg-cynog-T34429-Ab-1/ GM-Tg-cynog-T34429-Ab-2;
GM-Tg-felg-T34429-Ab-1/ GM-Tg-felg-T34429-Ab-2; GM-Tg-cang-T34429-Ab-1/ GM-Tg-cang-T34429-Ab-2;
GM-Tg-bovg-T34429-Ab-1/ GM-Tg-bovg-T34429-Ab-2; GM-Tg-equg-T34429-Ab-1/ GM-Tg-equg-T34429-Ab-2
Products NameAnti-CHRNA7 monoclonal antibody
Formatmab
Target NameCHRNA7
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CHRNA7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ACHA7/ CHRNA7/ CHRNA7-2 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP001474human CHRNA7 Lentivirus particle
    ORF Viral VectorpGMLP001474human CHRNA7 Lentivirus plasmid
    ORF Viral VectorpGMLPm005053mouse Chrna7 Lentivirus plasmid
    ORF Viral VectorvGMLPm005053mouse Chrna7 Lentivirus particle


    Target information

    Target IDGM-T34429
    Target NameCHRNA7
    Gene ID1139,25302,574230,488696,751113
    Gene Symbol and SynonymsBTX,CHRNA7,CHRNA7-2,NACHRA7,NARAD,nica7
    Uniprot AccessionP36544,Q05941,Q866A2
    Uniprot Entry NameACHA7_HUMAN,ACHA7_MACMU,ACHA7_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000175344
    Target ClassificationIon Channel

    The target: CHRNA7, gene name: CHRNA7, also named as CHRNA7-2, NACHRA7. The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that mediate fast signal transmission at synapses. The nAChRs are thought to be hetero-pentamers composed of homologous subunits. The proposed structure for each subunit is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. The protein encoded by this gene forms a homo-oligomeric channel, displays marked permeability to calcium ions and is a major component of brain nicotinic receptors that are blocked by, and highly sensitive to, alpha-bungarotoxin. Once this receptor binds acetylcholine, it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. This gene is located in a region identified as a major susceptibility locus for juvenile myoclonic epilepsy and a chromosomal location involved in the genetic transmission of schizophrenia. An evolutionarily recent partial duplication event in this region results in a hybrid containing sequence from this gene and a novel FAM7A gene. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.